{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120345","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.983114+00:00","generated_at":"2026-05-21T05:05:55.125719+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atara Q1 net income $38M; FDA lifts EBVALLO holds; $16M offering closes May 16","bullets":["Net income of $38.0M ($3.50 diluted EPS) vs net loss of $31.8M in Q1 2024; revenue $98.1M, up from $27.4M, driven by Pierre Fabre milestone.","Cash $13.8M at Mar 31, 2025; with $16M gross proceeds from May offering, expects runway into Q1 2026.","FDA lifted clinical holds on EBVALLO; Type A meeting Q2 2025 to address CRL; plans to resume Phase 3 ALLELE study.","Workforce reduced ~30% in May, retaining ~23 staff; FY2025 operating expenses expected to decrease ~65% YoY.","James Huang (Panacea) and Nachi Subramanian (Redmile) appointed to board effective after offering close."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120345","json":"https://secwatch.observer/filing/0001193125-25-120345.json","markdown":"https://secwatch.observer/filing/0001193125-25-120345.md","text":"https://secwatch.observer/filing/0001193125-25-120345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:05:55.125719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"843843dabb","claim":"James Huang was appointed as Director at Atara Biotherapeutics, Inc..","evidence_excerpt":"the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e5f03fa3f2","claim":"Nachi Subramanian was appointed as Director at Atara Biotherapeutics, Inc..","evidence_excerpt":"the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}